Ambrx and Hisun collaborate on development and commercialization of bispecifics for cancer
Clients Ambrx, Inc.
Jones Day represented Ambrx, Inc. in its collaboration with Zhejiang Hisun Pharmaceutical Company Ltd. for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for commercial supplies on a global basis.